Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead

Nektar Therapeutics (NASDAQ: NKTR) was a big winner in 2025. The clinical-stage biotech saw its shares soar on positive clinical developments. Let's give credit where credit is due. Nektar's rezpegaldesleukin is a promising clinical asset that could make waves in one of the largest therapeutic areas in the industry: immunology. And provided it can follow up recent clinical trial wins with more of the same, the stock could, once again, soar in 2026.However, Nektar Therapeutics is still a very risky stock. For a better and less volatile option in the same realm, investors should consider Madrigal Pharmaceuticals (NASDAQ: MDGL) instead. Here's why.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool